Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0392
Abstract: Immune checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Despite… read more here.
Keywords: immunologically cold; cold tumor; plus tivozanib; trial ... See more keywords